Drug intelligence / Profile preview

GEN1042 + pembrolizumab

Development stage: Unknown
Lead developer: Genmab
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GEN1042 + pembrolizumab is a combination immunotherapy regimen consisting of GEN1042 (DuoBody-CD40x4-1BB/BNT312), a bispecific antibody targeting CD40 and 4-1BB, and pembrolizumab, a PD-1 inhibitor. This combination is being investigated for its potential synergistic effects in enhancing anti-tumor immune responses in patients with advanced solid tumors. The therapy is administered via intravenous infusion and is currently being evaluated in clinical trials for various cancer types including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.

Targets

TNFRSF9 (CD137 extracellular domain)CD40 (Cluster of differentiation 40 receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GEN1042 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN1042 + pembrolizumab.

Explore the full profile